Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems
Open accessThe DOI matches its Crossref record; 194 of the 195 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative disorder. Most existing treatments only provide symptomatic solutions. Here, we introduce currently available commercial drugs and new therapeutics, including repositioned drugs, to treat AD. Despite tremendous efforts, treatments targeting the hallmarks of AD show limited efficacy. Challenges in treating AD are partly caused by difficulties in penetrating the blood–brain barrier (BBB). Recently, nanoparticle (NP)-based systems have shown promising potential as precision medicines that can effectively penetrate the BBB and enhance the targeting ability of numerous drugs. Here, we describe how NPs enter the brain by crossing, avoiding, or disrupting the BBB. In addition, we provide an overview of the action of NPs in the microenvironment of the brain for the treatment of AD. Diverse systems, including liposomes, micelles, polymeric NPs, solid-lipid NPs, and inorganic NPs, have been investigated for NP drug loading to relieve AD symptoms, target AD hallmarks, and target moieties to diagnose AD. We also highlight NP-based immunotherapy, which has recently gained special attention as a potential treatment option to disrupt AD progression. Overall, this review focuses on recently investigated NP systems that represent innovative strategies to understand AD pathogenesis and suggests treatment and diagnostic modalities to cure AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of nanoparticles (NP), with sizes between 10 and 1000 nm, capable of encapsulating therapeutic molecules by targeting transport processes in the CNS, can improve the crossing of molecules through the BBB in neurological disorders and reach targeted brain regions [29,30,31].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Circumvention of the BBB via local routes can involve invasive procedures, such as intracerebroventricular and intrathecal ones, that deliver drugs directly into the CSF or brain tissue but remain inefficient and clinically restricted [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, prolonged BBB disruption associated with long-term treatment raises safety concerns, as it may facilitate neurotoxic effects in the brain [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because liposomes are made with lipids, they are biocompatible, biodegradable, and can fuse to cell membranes. Additionally, due to their size, fluidity, permeability, and composition, they are suitable for controlled drug release, while being versatile in the drug encapsulation, as they can encapsulate both lipophilic and hydrophilic drugs (dual solubility) [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, some molecules can cross the BBB by two main pathways, transcellular or paracellular, through the cell or the intercellular space, respectively [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This drug is designed to act on the deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain [6].”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 1×
“The abnormal processing of amyloid precursor protein (APP) by β- and γ-secretases produces extracellular non-vascular accumulation of Aβ40 and Aβ42 peptides [22,23].”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“These latter preventive activities are supported by ApoE, which relies on TREM2 and activates microglia into the disease-associated microglia (DAM) state [174,175].”
BackgroundThe cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology
Zielińska, A., Carreiró, F., Oliveira, A. M., Neves, A., Pires, B., Venkatesh, D. N., Durazzo, A., Lucarini, M., Eder, P., Silva, A. M., et al. (2020) · Molecules · doi:10.3390/molecules25163731 · Cited by 1,560
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 2)
Honary, S., & Zahir, F. (2013) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v12i2.20 · Cited by 1,309
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties
Sukhanova, A., Bozrova, S., Sokolov, P., Berestovoy, M., Karaulov, A., & Nabiev, I. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2457-x · Cited by 1,107
Physical Principles of Nanoparticle Cellular Endocytosis
Zhang, S., Gao, H., & Bao, G. (2015) · ACS Nano · doi:10.1021/acsnano.5b03184 · Cited by 1,103
Cerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102 · cited 1×
“Different types of cerebrovascular deficiency, such as reduced blood flow to the brain or impaired microvascular integrity in cortical regions, can occupy preliminary or intermediate positions in a series of events that result in cognitive impairment causing AD [39].”
BackgroundProinflammatory Cytokines, Aging, and Age-Related Diseases
Michaud, M., Balardy, L., Moulis, G., Gaudin, C., Peyrot, C., Vellas, B., Cesari, M., & Nourhashemi, F. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.009 · Cited by 1,094 · cited 1×
“These responses orchestrate the inflammatory response in patients with AD [47,48].”
BackgroundButterfield, D. A., & Lauderback, C. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00794-3 · Cited by 1,001
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837 · cited 4×
“This pathway induces endocytosis via clathrin-coated pits or caveolae, similar to AMT [67].”
BackgroundInfluentialThe Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 745
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · cited 1×
“However, these medicines do not correlate with the fundamental pathology of AD [5].”
BackgroundAlzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Gong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
Tau protein kinases: Involvement in Alzheimer's disease
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631
Mehta, D., Jackson, R., Paul, G., Shi, J., & Sabbagh, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323868 · Cited by 607
Risk factors for Alzheimer’s disease
A. Armstrong, R. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.85929 · Cited by 606
Butterfield, D. A., Reed, T., Newman, S. F., & Sultana, R. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.037 · Cited by 564
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
Alzheimer’s disease drug development pipeline: 2021
Cummings, J., Lee, G., Zhong, K., Fonseca, J., & Taghva, K. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12179 · Cited by 539 · cited 1×
“Over 50 million individuals worldwide are facing disruptive cognitive functions, and the number of newly diagnosed cases is rapidly increasing due to increases in the human life expectancy and the aging of populations [1,2].”
BackgroundThe role of zinc, copper, manganese and iron in neurodegenerative diseases
Mezzaroba, L., Alfieri, D. F., Colado Simão, A. N., & Vissoci Reiche, E. M. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.07.007 · Cited by 524
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
Pluvinage, J. V., Haney, M. S., Smith, B. A. H., Sun, J., Iram, T., Bonanno, L., Li, L., Lee, D. P., Morgens, D. W., Yang, A. C., et al. (2019) · Nature · doi:10.1038/s41586-019-1088-4 · Cited by 459 · cited 1×
“CD-22 suppression facilitates the removal of Aβ fibrils from the brain, which could be a viable strategy to reduce the progression of neuroinflammation and AD [49].”
BackgroundCurrent understanding of metal ions in the pathogenesis of Alzheimer’s disease
Wang, L., Yin, Y.-L., Liu, X.-Z., Shen, P., Zheng, Y.-G., Lan, X.-R., Lu, C.-B., & Wang, J.-Z. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00189-z · Cited by 454
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451 · cited 1×
“Although these strategies provide new alternatives to overcome the BBB, it is not certain whether translational, repetitive, and prolonged BBB opening might also induce neurotoxicity [86,103].”
BackgroundAmyloid-β immunotherapy for Alzheimer's disease: the end of the beginning
Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436
Daulatzai, M. A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23777 · Cited by 429
Baruch, K., Deczkowska, A., Rosenzweig, N., Tsitsou-Kampeli, A., Sharif, A. M., Matcovitch-Natan, O., Kertser, A., David, E., Amit, I., & Schwartz, M. (2016) · Nature Medicine · doi:10.1038/nm.4022 · Cited by 425 · cited 2×
“Immune checkpoint inhibitors also enhance the systemic adaptive immune response that might combat neurodegeneration in AD [179,180].”
BackgroundActive targeting of brain tumors using nanocarriers
Béduneau, A., Saulnier, P., & Benoit, J.-P. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.06.011 · Cited by 424
Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles
Banerjee, T., Mitra, S., Kumar Singh, A., Kumar Sharma, R., & Maitra, A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00267-3 · Cited by 409
Economic burden of Alzheimer disease and managed care considerations
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88482 · Cited by 398
Hou, K., Zhao, J., Wang, H., Li, B., Li, K., Shi, X., Wan, K., Ai, J., Lv, J., Wang, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18525-2 · Cited by 373 · cited 1×
“, designed AuNPs loaded with stabilized L- and D-glutathione, which crossed the BBB by intravenous administration and inhibited Aβ42 without noticeable toxicity [162].”
BackgroundRole of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370 · cited 2×
“BBB dysfunction is directly correlated with amyloid and tau pathology in AD [8].”
BackgroundHypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease
Arnsten, A. F. T., Datta, D., Del Tredici, K., & Braak, H. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12192 · Cited by 361 · cited 1×
“Insoluble NFTs hinder cytoplasmic functions, deteriorates transportation across axons, and thus leads to neuronal cell death [32].”
BackgroundSynaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria
John, A., & Reddy, P. H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101208 · Cited by 359
Han, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau
Hardy, J., Duff, K., Hardy, K. G., Perez-Tur, J., & Hutton, M. (1998) · Nature Neuroscience · doi:10.1038/1565 · Cited by 347
Loureiro, J., Andrade, S., Duarte, A., Neves, A., Queiroz, J., Nunes, C., Sevin, E., Fenart, L., Gosselet, F., Coelho, M., et al. (2017) · Molecules · doi:10.3390/molecules22020277 · Cited by 341
Cano, A., Ettcheto, M., Chang, J.-H., Barroso, E., Espina, M., Kühne, B. A., Barenys, M., Auladell, C., Folch, J., Souto, E. B., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.010 · Cited by 337
Fang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-139634 · Cited by 335
Kumagai, A. K., Eisenberg, J. B., & Pardridge, W. M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48160-4 · Cited by 325
Focused ultrasound-mediated drug delivery through the blood–brain barrier
Burgess, A., Shah, K., Hough, O., & Hynynen, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1028369 · Cited by 323
Zheng, W.-H., Bastianetto, S., Mennicken, F., Ma, W., & Kar, S. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00404-9 · Cited by 321
The LPS receptor (CD14) links innate immunity with Alzheimer's disease
Fassbender, K., Walter, S., Kühl, S., Landmann, R., Ishii, K., Bertsch, T., Stalder, A. K., Muehlhauser, F., Liu, Y., Ulmer, A. J., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0364fje · Cited by 307 · cited 1×
“Since AD brains become incorporated with a high concentration of Aβ fibrils for many years, this interaction is sufficient to maintain chronic neuroinflammation [176].”
BackgroundBlood-Brain Delivery Methods Using Nanotechnology
Teleanu, D. M., Chircov, C., Grumezescu, A. M., Volceanov, A., & Teleanu, R. I. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040269 · Cited by 305
House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., & Exley, C. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6310 · Cited by 294
Role of RAGE in Alzheimer’s Disease
Cai, Z., Liu, N., Wang, C., Qin, B., Zhou, Y., Xiao, M., Chang, L., Yan, L.-J., & Zhao, B. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0233-3 · Cited by 285
Nano carriers for drug transport across the blood–brain barrier
Li, X., Tsibouklis, J., Weng, T., Zhang, B., Yin, G., Feng, G., Cui, Y., Savina, I. N., Mikhalovska, L. I., Sandeman, S. R., et al. (2017) · Journal of Drug Targeting · doi:10.1080/1061186x.2016.1184272 · Cited by 282
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279 · cited 1×
“This route has been shown to be inefficient and clinically restricted [77,78].”
BackgroundNeurobiology of Alzheimer′s disease
Mohandas, E., Rajmohan, V, & Raghunath, B. (2009) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.44908 · Cited by 268
Fan, S., Zheng, Y., Liu, X., Fang, W., Chen, X., Liao, W., Jing, X., Lei, M., Tao, E., Ma, Q., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1461955 · Cited by 258
Dhawan, S., Kapil, R., & Singh, B. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01225.x · Cited by 256
Yang, Z.-Z., Zhang, Y.-Q., Wang, Z.-Z., Wu, K., Lou, J.-N., & Qi, X.-R. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.009 · Cited by 248
Muntimadugu, E., Dhommati, R., Jain, A., Challa, V. G. S., Shaheen, M., & Khan, W. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.012 · Cited by 240
Shah, B., Khunt, D., Bhatt, H., Misra, M., & Padh, H. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.07.002 · Cited by 237
Wimmer, I., Tietz, S., Nishihara, H., Deutsch, U., Sallusto, F., Gosselet, F., Lyck, R., Muller, W. A., Lassmann, H., & Engelhardt, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00711 · Cited by 233
Peptide/protein vaccine delivery system based on PLGA particles
Allahyari, M., & Mohit, E. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1102804 · Cited by 232
Rosenzweig, N., Dvir-Szternfeld, R., Tsitsou-Kampeli, A., Keren-Shaul, H., Ben-Yehuda, H., Weill-Raynal, P., Cahalon, L., Kertser, A., Baruch, K., Amit, I., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08352-5 · Cited by 227
Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects
Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226 · cited 1×
“Intracellular cholesterol is also involved in the regulation of APP processing by directly modulating secretase activity [45].”
BackgroundImmunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease
Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219 · cited 1×
“Polymeric NPs are able to open tight junctions in the BBB and provide loaded substances with a camouflaging membrane barrier, which protects drugs from enzymatic degradation and achieves sustained drug release [16].”
BackgroundReview of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lu, A., & Yang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020381 · Cited by 213
Potential neurotoxicity of nanoparticles
Hu, Y.-L., & Gao, J.-Q. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.026 · Cited by 213
Allémann, E., Leroux, J.-C., Gurny, R., & Doelker, E. (1993) · Pharmaceutical Research · doi:10.1023/a:1018970030327 · Cited by 212
Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease
Sun, D., Li, N., Zhang, W., Zhao, Z., Mou, Z., Huang, D., Liu, J., & Wang, W. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2016.08.052 · Cited by 199
Yin, T., Yang, L., Liu, Y., Zhou, X., Sun, J., & Liu, J. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.06.035 · Cited by 197
Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer's disease
Pinheiro, R. G. R., Granja, A., Loureiro, J. A., Pereira, M. C., Pinheiro, M., Neves, A. R., & Reis, S. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105314 · Cited by 190
Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders
Islam, S. U., Shehzad, A., Ahmed, M. B., & Lee, Y. S. (2020) · Molecules · doi:10.3390/molecules25081929 · Cited by 184
Polyphenols as Potential Metal Chelation Compounds Against Alzheimer’s Disease
Lakey-Beitia, J., Burillo, A. M., La Penna, G., Hegde, M. L., & Rao, K. S. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-200185 · Cited by 177
Meng, F., Asghar, S., Gao, S., Su, Z., Song, J., Huo, M., Meng, W., Ping, Q., & Xiao, Y. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.06.025 · Cited by 176
Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer’s Disease
d‘Errico, P., & Meyer-Luehmann, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00265 · Cited by 175
Cortical iron reflects severity of Alzheimer's disease
van Duijn, S., Bulk, M., van Duinen, S. G., Nabuurs, R. J. A., van Buchem, M. A., van der Weerd, L., & Natté, R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161143 · Cited by 172
Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease
Moore, A. H., & O’Banion, M. K. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00162-x · Cited by 171
Lu, Y., Guo, Z., Zhang, Y., Li, C., Zhang, Y., Guo, Q., Chen, Q., Chen, X., He, X., Liu, L., et al. (2019) · Advanced Science · doi:10.1002/advs.201801586 · Cited by 164
B6 Peptide-Modified PEG-PLA Nanoparticles for Enhanced Brain Delivery of Neuroprotective Peptide
Liu, Z., Gao, X., Kang, T., Jiang, M., Miao, D., Gu, G., Hu, Q., Song, Q., Yao, L., Tu, Y., et al. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400055h · Cited by 163
Gold Nanoparticles Treatment Reverses Brain Damage in Alzheimer’s Disease Model
Tramontin, N. D. S., da Silva, S., Arruda, R., Simon, K. U., Canteiro, P. B., Silveira, G. D. B., Mendes, C., Silveira, P. C. L., & Muller, A. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01780-w · Cited by 163
Rotman, M., Welling, M. M., Bunschoten, A., de Backer, M. E., Rip, J., Nabuurs, R. J. A., Gaillard, P. J., van Buchem, M. A., van der Maarel, S. M., & van der Weerd, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.012 · Cited by 160
Kong, L., Li, X.-T., Ni, Y.-N., Xiao, H.-H., Yao, Y.-J., Wang, Y.-Y., Ju, R.-J., Li, H.-Y., Liu, J.-J., Fu, M., et al. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s239608 · Cited by 158
Ullah, Z., Al-Asmari, A., Tariq, M., & Fatani, A. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s93937 · Cited by 157
Arora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149
Razzino, C. A., Serafín, V., Gamella, M., Pedrero, M., Montero‐Calle, A., Barderas, R., Calero, M., Lobo, A. O., Yáñez‐Sedeño, P., Campuzano, S., et al. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112238 · Cited by 147
Li, W., Zhou, Y., Zhao, N., Hao, B., Wang, X., & Kong, P. (2012) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2012.04.012 · Cited by 141
Role of metals in Alzheimer’s disease
Das, N., Raymick, J. B., & Sarkar, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00765-w · Cited by 141
Yang, P., Sheng, D., Guo, Q., Wang, P., Xu, S., Qian, K., Li, Y., Cheng, Y., Wang, L., Lu, W., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119844 · Cited by 137
Misra, S., Chopra, K., Sinha, V. R., & Medhi, B. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1089956 · Cited by 136 · cited 1×
“, formulated galantamine hydrobromide-loaded SLNs, which offered enhanced in vitro drug release (>90% during 24 h) and also displayed a substantial memory restoration capacity in cognitive-deficit AD rodents [123].”
BackgroundTopal, G. R., Mészáros, M., Porkoláb, G., Szecskó, A., Polgár, T. F., Siklós, L., Deli, M. A., Veszelka, S., & Bozkir, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010038 · Cited by 132
Candela, P., Gosselet, F., Saint-Pol, J., Sevin, E., Boucau, M.-C., Boulanger, E., Cecchelli, R., & Fenart, L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100462 · Cited by 128
Mars, A., Hamami, M., Bechnak, L., Patra, D., & Raouafi, N. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.06.075 · Cited by 127 · cited 1×
“7% relative standard deviation (RSD) toward targeted ApoE4 DNA, even in human blood plasma [161].”
BackgroundGonzalez-Carter, D., Liu, X., Tockary, T. A., Dirisala, A., Toh, K., Anraku, Y., & Kataoka, K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002016117 · Cited by 127
Mendes, I. T., Ruela, A. L. M., Carvalho, F. C., Freitas, J. T. J., Bonfílio, R., & Pereira, G. R. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.02.007 · Cited by 125
Gothwal, A., Kumar, H., Nakhate, K. T., Ajazuddin, Dutta, A., Borah, A., & Gupta, U. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00505 · Cited by 124
Liu, Y., Gong, Y., Xie, W., Huang, A., Yuan, X., Zhou, H., Zhu, X., Chen, X., Liu, J., Liu, J., et al. (2020) · Nanoscale · doi:10.1039/c9nr09713a · Cited by 123
Glut1/SLC2A1 is crucial for the development of the blood‐brain barrier in vivo
Zheng, P., Romme, E., Spek, P. J. V. D., Dirven, C. M. F., Willemsen, R., & Kros, J. M. (2010) · Annals of Neurology · doi:10.1002/ana.22318 · Cited by 120
Dai, H., Navath, R. S., Balakrishnan, B., Guru, B. R., Mishra, M. K., Romero, R., Kannan, R. M., & Kannan, S. (2010) · Nanomedicine · doi:10.2217/nnm.10.89 · Cited by 120
Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery
Lungare, S., Hallam, K., & Badhan, R. K. S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.042 · Cited by 119
Vakilinezhad, M. A., Amini, A., Javar, H. A., Zarandi, B. F. B. B., Montaseri, H., & Dinarvand, R. (2018) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-018-0221-5 · Cited by 119
Picone, P., Ditta, L. A., Sabatino, M. A., Militello, V., San Biagio, P. L., Di Giacinto, M. L., Cristaldi, L., Nuzzo, D., Dispenza, C., Giacomazza, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.057 · Cited by 118
Baysal, İ., Uçar, G., Gültekinoğlu, M., Ulubayram, K., & Ciftci, S. Y. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1527-4 · Cited by 118
Nazıroğlu, M., Muhamad, S., & Pecze, L. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1324781 · Cited by 118
Sanati, M., Khodagholi, F., Aminyavari, S., Ghasemi, F., Gholami, M., Kebriaeezadeh, A., Sabzevari, O., Hajipour, M. J., Imani, M., Mahmoudi, M., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00622 · Cited by 112
Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's
Nirale, P., Paul, A., & Yadav, K. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117394 · Cited by 112
Focused Ultrasound and Microbubbles-Mediated Drug Delivery to Brain Tumor
Wu, S.-K., Tsai, C.-L., Huang, Y., & Hynynen, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010015 · Cited by 112
Theories of Aging and the Prevalence of Alzheimer’s Disease
Trevisan, K., Cristina-Pereira, R., Silva-Amaral, D., & Aversi-Ferreira, T. A. (2019) · BioMed Research International · doi:10.1155/2019/9171424 · Cited by 111
Liu, W., Wang, W., Dong, X., & Sun, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c02342 · Cited by 110
Frölich, L. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200083 · Cited by 110
Advances in developing therapeutic strategies for Alzheimer's disease
Nguyen, T. T., Nguyen, T. T. D., Nguyen, T. K. O., Vo, T. K., & Vo, V. G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111623 · Cited by 107
Treatment of Alzheimer’s diseases using donepezil nanoemulsion: an intranasal approach
Kaur, A., Nigam, K., Bhatnagar, I., Sukhpal, H., Awasthy, S., Shankar, S., Tyagi, A. K., & Dang, S. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00754-z · Cited by 106
Saffari, P. M., Alijanpour, S., Takzaree, N., Sahebgharani, M., Etemad-Moghadam, S., Noorbakhsh, F., & Partoazar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117861 · Cited by 106
Memantine nanoemulsion: a new approach to treat Alzheimer’s disease
Kaur, A., Nigam, K., Srivastava, S., Tyagi, A., & Dang, S. (2020) · Journal of Microencapsulation · doi:10.1080/02652048.2020.1756971 · Cited by 106
Zhou, H., Gong, Y., Liu, Y., Huang, A., Zhu, X., Liu, J., Yuan, G., Zhang, L., Wei, J.-A., & Liu, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119822 · Cited by 105
Yadav, A., Sunkaria, A., Singhal, N. K., & Sandhir, R. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.001 · Cited by 103
Intranasal drug delivery for treatment of Alzheimer’s disease
Fonseca, L., Lopes, J. A., Vieira, J., Viegas, C., Oliveira, C. S., Hartmann, R. P., & Fonte, P. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00940-7 · Cited by 100
Nanomedicine for the Treatment of Alzheimer’s Disease
Gregori, M., Masserini, M., & Mancini, S. (2015) · Nanomedicine · doi:10.2217/nnm.14.206 · Cited by 99
Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer’s Disease
Manek, E., Darvas, F., & Petroianu, G. A. (2020) · Molecules · doi:10.3390/molecules25204866 · Cited by 97
Huttunen, J., Peltokangas, S., Gynther, M., Natunen, T., Hiltunen, M., Auriola, S., Ruponen, M., Vellonen, K.-S., & Huttunen, K. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-49009-z · Cited by 96
Advances in microphysiological blood-brain barrier (BBB) models towards drug delivery
Lee, C. S., & Leong, K. W. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.06.009 · Cited by 94
Tak, K., Sharma, R., Dave, V., Jain, S., & Sharma, S. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00273 · Cited by 93
Dara, T., Vatanara, A., Sharifzadeh, M., Khani, S., Vakilinezhad, M. A., Vakhshiteh, F., Nabi Meybodi, M., Sadegh Malvajerd, S., Hassani, S., & Mosaddegh, M. H. (2019) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2019.107082 · Cited by 91
Song, J., Lu, C., Leszek, J., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810118 · Cited by 91
Scheld, W. M. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.supplement_7.s1669 · Cited by 90
Pharmacological Modification of Bradykinin Induced Breakdown of the Blood-brain Barrier
Raymond, J. J., Robertson, D. M., & Dinsdale, H. B. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100036301 · Cited by 87
Enteshari Najafabadi, R., Kazemipour, N., Esmaeili, A., Beheshti, S., & Nazifi, S. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0249-7 · Cited by 87
The Role of the Blood Brain Barrier in Neurodegenerative Disorders and their Treatment
Palmer, A. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110368 · Cited by 85
Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice
Householder, K. T., Dharmaraj, S., Sandberg, D. I., Wechsler-Reya, R. J., & Sirianni, R. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-49028-w · Cited by 83 · cited 1×
“, intrathecally administered PEG-NPs into healthy mice and showed rapid distribution through the SAS with a reproducible pattern of brain delivery [84].”
BackgroundTau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice
Ittner, A., Bertz, J., Suh, L. S., Stevens, C. H., Götz, J., & Ittner, L. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.12821 · Cited by 82
Agwa, M. M., Abdelmonsif, D. A., Khattab, S. N., & Sabra, S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.058 · Cited by 82
Silva-Abreu, M., Calpena, A. C., Andrés-Benito, P., Aso, E., Romero, I. A., Roig-Carles, D., Gromnicova, R., Espina, M., Ferrer, I., García, M. L., et al. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s171490 · Cited by 81
Sunena, Singh, S. K., & Mishra, D. N. (2018) · Current Drug Delivery · doi:10.2174/1567201815666181004094707 · Cited by 80
Chauhan, M. K., & Sharma, P. K. (2019) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2019.104794 · Cited by 80
Bhatt, P. C., Srivastava, P., Pandey, P., Khan, W., & Panda, B. P. (2016) · RSC Advances · doi:10.1039/c5ra19113k · Cited by 79
Hroudová, J., Singh, N., Fišar, Z., & Ghosh, K. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.084 · Cited by 78
The cholinergic deficit in Alzheimer's disease.
Whitehouse, P. J. (1998) · PubMed · Cited by 76
Neurotoxicity of metal‐containing nanoparticles and implications in glial cells
Chang, X., Li, J., Niu, S., Xue, Y., & Tang, M. X. (2020) · Journal of Applied Toxicology · doi:10.1002/jat.4037 · Cited by 74
Fong, L. K., Yang, M. M., dos Santos Chaves, R., Reyna, S. M., Langness, V. F., Woodruff, G., Roberts, E. A., Young, J. E., & Goldstein, L. S. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000441 · Cited by 72
Jiang, Y., Liu, C., Zhai, W., Zhuang, N., Han, T., & Ding, Z. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s214657 · Cited by 71
Yin, L., Wang, Y., Tan, R., Li, H., & Tu, Y. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04710-7 · Cited by 71
Zhu, J., Zhang, Y., Chen, X., Zhang, Y., Zhang, K., Zheng, H., Wei, Y., Zheng, H., Zhu, J., Wu, F., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.076 · Cited by 69
Dual ligand immunoliposomes for drug delivery to the brain
Loureiro, J. A., Gomes, B., Fricker, G., Cardoso, I., Ribeiro, C. A., Gaiteiro, C., Coelho, M. A. N., Pereira, M. D. C., & Rocha, S. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.06.067 · Cited by 68
Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease
Turab Naqvi, A. A., Hasan, G. M., & Hassan, M. I. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200106125910 · Cited by 65
Dendrimers reduce toxicity of Aβ 1-28 peptide during aggregation and accelerate fibril formation
Klajnert‐Maculewicz, B., Wasiak, T., Йонов, М., Fernandez‐Villamarin, M., Sousa‐Herves, A., Correa, J., Riguera, R., & Fernández-Megía, E. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.03.005 · Cited by 65
The CD157-Integrin Partnership Controls Transendothelial Migration and Adhesion of Human Monocytes
Buono, N. L., Parrotta, R., Morone, S., Bovino, P., Nacci, G., Ortolan, E., Horenstein, A. L., Inzhutova, A., Ferrero, E., & Funaro, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.227876 · Cited by 64
Matheou, C. J., Younan, N. D., & Viles, J. H. (2015) · Biochemical Journal · doi:10.1042/bj20141168 · Cited by 64
Latta‐Mahieu, M., Elmer, B., Bretteville, A., Wang, Y., Lopez‐Grancha, M., Goniot, P., Moindrot, N., Ferrari, P., Blanc, V., Schussler, N., et al. (2018) · Glia · doi:10.1002/glia.23260 · Cited by 64
Cheng, C.-S., Liu, T.-P., Chien, F.-C., Mou, C.-Y., Wu, S.-H., & Chen, Y.-P. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b02797 · Cited by 63
Chemicals used for the induction of Alzheimer’s disease-like cognitive dysfunctions in rodents
Mahdi, O., Baharuldin, M. T. H., Nor, N. H. M., Chiroma, S. M., Jagadeesan, S., & Moklas, M. A. M. (2019) · Biomedical Research and Therapy · doi:10.15419/bmrat.v6i11.575 · Cited by 61
Progress of RAGE Molecular Imaging in Alzheimer’s Disease
Kong, Y., Liu, C., Zhou, Y., Qi, J., Zhang, C., Sun, B., Wang, J., & Guan, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00227 · Cited by 61
Nanaki, S. G., Spyrou, K., Bekiari, C., Veneti, P., Baroud, T. N., Karouta, N., Grivas, I. N., Papadopoulos, G. C., Gournis, D., & Bikiaris, D. Ν. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030227 · Cited by 60
Lopez-Barbosa, N., Garcia, J. G., Cifuentes, J., Castro, L. M., Vargas, F., Ostos, C., Cardona-Gomez, G. P., Hernandez, A. M., & Cruz, J. C. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1775724 · Cited by 59
Margel, S., Skaat, H., Corem‐Salkmon, E., Grinberg, I., Last, D., Goez, D., & Mardor, Y. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s52833 · Cited by 58
Chen, L., Lin, J., Yi, J., Weng, Q., Zhou, Y., Han, Z., Li, C., Chen, J., & Zhang, Q. Y. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01909-9 · Cited by 58
Pagar, K. P., & Vavia, P. (2013) · Scientia Pharmaceutica · doi:10.3797/scipharm.1211-20 · Cited by 54
Noor, N. A., Hosny, E. N., Khadrawy, Y. A., Mourad, I. M., Othman, A. I., Ezz, H. S. A., & Mohammed, H. S. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-021-00897-z · Cited by 54
Prabakaran, A., Agrawal, M., Dethe, M. R., Ahmed, H., Yadav, A. K., Gupta, U. D., & Alexander, A. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2029845 · Cited by 48
Mann, K. M. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh199 · Cited by 48
Can immunotherapy treat neurodegeneration?
Schwartz, M. (2017) · Science · doi:10.1126/science.aai8231 · Cited by 47
A nanoformulation for the preferential accumulation in adult neurogenic niches
Praça, C., Rai, A., Santos, T., Cristovão, A. C., Pinho, S. L., Cecchelli, R., Dehouck, M.-P., Bernardino, L., & Ferreira, L. S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.013 · Cited by 46
Zhou, X., Hu, S., Wang, S., Pang, Y., Lin, Y., & Li, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.778613 · Cited by 46
Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain
Pardridge, W. M. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.602236 · Cited by 46
Nanomedicine for the Treatment of Alzheimer's Disease
Formicola, B., Cox, A., dal Magro, R., Masserini, M., & Re, F. (2019) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2019.2837 · Cited by 46
Hao, S., Li, X., Han, A., Yang, Y., Fang, G., Liu, J., & Wang, S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00469 · Cited by 44
Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems
Altinoglu, G., & Adalı, T. (2019) · Current Drug Targets · doi:10.2174/1389450120666191118123151 · Cited by 44
Méphon-Gaspard, A., Boca, M., Pioche-Durieu, C., Desforges, B., Burgo, A., Hamon, L., Piétrement, O., & Pastré, D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2216-z · Cited by 43
Preparation of Trojan Horse Liposomes (THLs) for Gene Transfer across the Blood-Brain Barrier
Pardridge, W. M. (2010) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot5407 · Cited by 42
Nanoliposomes as a Therapeutic Tool for Alzheimer’s Disease
Ordóñez‐Gutiérrez, L., & Wandosell, F. G. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00020 · Cited by 42
Breuer, W., Ghoti, H., Shattat, A., Goldfarb, A., Koren, A., Levin, C., Rachmilewitz, E., & Cabantchik, Z. I. (2012) · American Journal of Hematology · doi:10.1002/ajh.22203 · Cited by 41
Cholesterol-lowering drugs reduce APP processing to Aβ by inducing APP dimerization
Langness, V. F., van der Kant, R., Das, U., Wang, L., Chaves, R. D. S., & Goldstein, L. S. B. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-05-0345 · Cited by 41
Li, Y., Lim, E., Fields, T., Wu, H., Xu, Y., Wang, Y. A., & Mao, H. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00086 · Cited by 36
Yin, H., Jin, S., Xu, H., Dong, J., Zheng, D., Lu, X., & Li, X. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1897 · Cited by 36
DeRidder, L. B., Sharma, A., Liaw, K., Sharma, R. B., John, J., Kannan, S., & Kannan, R. M. (2021) · Nanoscale · doi:10.1039/d0nr05958g · Cited by 33
Wang, S., Li, C., Xia, Y., Chen, S., Robert, J., Banquy, X., Huang, R., Qi, W., He, Z., & Su, R. (2020) · iScience · doi:10.1016/j.isci.2020.101044 · Cited by 32
Duwa, R., Jeong, J., & Yook, S. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00521-3 · Cited by 32
Geng, H., Yuan, H., Qiu, L., Gao, D. M., Cheng, Y., & Xing, C. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01863e · Cited by 31
Kofoed, R. H., Heinen, S., Silburt, J., Dubey, S., Dibia, C. L., Maes, M. S., Simpson, E. M., Hynynen, K., & Aubert, I. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.001 · Cited by 31
Obst, J., Mancuso, R., Simon, E., & Gómez‐Nicola, D. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.08.006 · Cited by 28
Copper Ion Uptake by Chitosan in the Presence of Amyloid-β and Histidine
Mahl, C. R. A., Taketa, T. B., Neto, J. B. M. R., Almeida, W. P., & Beppu, M. M. (2019) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-019-03120-z · Cited by 23
Nguyen, T. T., Vo, T. K., & Vo, G. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_13 · Cited by 20
Magnetic nanoemulsions as candidates for Alzheimer’s disease dual imaging theranostics
Antonoglou, O., Giannousi, K., Mourdikoudis, S., & Dendrinou-Samara, C. (2020) · Nanotechnology · doi:10.1088/1361-6528/abac35 · Cited by 17
Heydari, S., Hedayati, M., Saadat, F., Abedinzade, M., Nikokar, I., Aboutaleb, E., Khafri, A., & Mokarram, A. R. (2019) · Pharmacological Reports · doi:10.1007/s43440-019-00017-w · Cited by 15
Yurek, D. M., Hasselrot, U., Cass, W. A., Sesenoglu‐Laird, O., Padegimas, L., & Cooper, M. J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.026 · Cited by 10
Liposome Enhanced Detection of Amyloid Protein Aggregates
Kocsis, I., Sanna, E., & Hunter, C. A. (2021) · Organic Letters · doi:10.1021/acs.orglett.0c03597 · Cited by 10
Liu, E. Y. L., Mak, S., Kong, X., Xia, Y., Kwan, K. K., Xu, M. L., & Tsim, K. W. K. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.121.000269 · Cited by 9
Akanuma, S. (2020) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.20-00127 · Cited by 5
Research works printed but not linked: 1
- Chung, E.J., Leon, L., and Rinaldi, C. (2020). Chapter 21—Nanoemulsions. Nanoparticles for Biomedical Applications, Elsevier.
Cited by
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Levodopa-loaded nanoparticles for the treatment of Parkinson's disease
van Vliet, E. F., Knol, M. J., Schiffelers, R. M., Caiazzo, M., & Fens, M. H. A. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.026 · Cited by 97
Pei, J., Kumarasamy, R. V., Jayaraman, S., Kanniappan, G. V., Long, Q., & Palanisamy, C. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102665 · Cited by 97
Khalid-Salako, F. A., Khaligh, S. S., Fathi, F., Demirci, O. C., Öncer, N., Kurt, H., & Yüce, M. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07366 · Cited by 83
Quantum dots: The cutting-edge nanotheranostics in brain cancer management
Chakraborty, P., Das, S. S., Dey, A., Chakraborty, A., Bhattacharyya, C., Kandimalla, R. J. L., Mukherjee, B., Gopalakrishnan, A. V., Singh, S. K., Kant, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.047 · Cited by 69
Metadata
- Authors
- Poudel, P., & Park, S.
- Affiliations
- Keimyung University (KR)
- Corresponding author
- Park, Soyeun
- ORCID
- Park, Soyeun
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-04-11
- Volume
- 14
- Issue
- 4
- Pages
- 835
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9026997
- OpenAlex
- W4223478480
- Cited by
- 124
- References
- 195
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 33 · 2023: 17 · 2022: 9
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Keimyung University (2019)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- Alzheimer's disease, nanoparticle drug delivery, blood-brain barrier, liposomes, micelles, polymeric nanoparticles, solid lipid nanoparticles, inorganic nanoparticles, Alzheimer's disease therapeutics, Alzheimer's disease diagnosis, neurodegeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.